A unit of Chinese contract drugmaker Wuxi Biologics has experienced overwhelming demand for its initial public offering (IPO) in Hong Kong, closing its order book early and potentially pricing the deal at the top of its marketed range, according to sources familiar with the matter. This is a remarkable occurrence in a year that has seen a turbulent market for listings in Hong … [Read more...] about Wuxi XDC Cayman: Strong Demand for IPO in Hong Kong
IPO
Lalatech Files for IPO in Hong Kong
Lalatech, a logistics company backed by private-equity firms Hillhouse Capital and Sequoia Capital, has recently submitted an application for an initial public offering (IPO) in Hong Kong. This move makes Lalatech the latest company in the logistics industry aiming to utilize the city's thriving market. The Hong Kong-based company, as per the stock-exchange filing on Thursday, … [Read more...] about Lalatech Files for IPO in Hong Kong
Investor Interest in Arm Holdings PLC Dips After Strong Debut
Arm Holdings PLC, a leading semiconductor design company, has experienced a decline in investor interest following its impressive initial public offering (IPO) debut. The company's stock (ARM, -4.40%) recorded its third consecutive loss on Tuesday, falling by 4.1% in midday trading and losing a total of 12.5% over the past three sessions. During its first day of trading, Arm … [Read more...] about Investor Interest in Arm Holdings PLC Dips After Strong Debut
Instacart: A Test for Investors’ Appetite in the Gig Economy
The online grocery delivery company, Instacart, is making waves in the retail brokerage accounts as it prepares for its initial public offering (IPO). Set to trade under the ticker symbol "CART," Instacart's valuation is set at approximately $9.6 billion, according to a recent filing. This valuation represents a significant increase from its previous assessments, reflecting the … [Read more...] about Instacart: A Test for Investors’ Appetite in the Gig Economy
Neumora Therapeutics Plans IPO
Neumora Therapeutics, a clinical-stage biopharmaceutical company specializing in brain diseases, has announced its plan to launch an initial public offering (IPO) to raise capital. Backed by Amgen, the company intends to sell 14.7 million shares at a price range of $16 to $18 per share. At the midpoint of $17 per share, Neumora expects to generate approximately $227.5 million … [Read more...] about Neumora Therapeutics Plans IPO
